Cardiff Oncology trades as a micro-cap, clinical-stage biotechnology stock that has remained volatile in a difficult funding environment for pre-revenue drug developers. After climbing through the first half of September 2026, the stock drifted lower through October and early November, pressured by investor concerns over dilution and a legal dispute with its onvansertib licensor. The shares fell to an intraday low near $0.72 in mid-November before staging a sharp recovery on the FDA Fast Track designation, which drove unusually heavy trading volume and lifted the stock back toward the mid-$0.80s. Broader sentiment across small-cap biotech remains cautious, with clinical catalysts and balance-sheet durability serving as the dominant valuation drivers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cardiff Oncology is a San Diego-based biotechnology company focused on developing therapies that inhibit PLK1, a validated oncology target, with the goal of treating RAS-mutated cancers. Its lead asset, onvansertib, is being evaluated in the randomized, controlled CRDF-004 Phase 2 trial in combination with FOLFIRI/bevacizumab for first-line RAS-mutated metastatic colorectal cancer (mCRC). In that study, the 30 mg onvansertib arm had not reached median progression-free survival, compared with roughly 11 months in the standard-of-care arms. The company is preparing a registrational global Phase 3 trial, CRDF-005, targeting approximately 640 patients, with potential initiation in the first quarter of 2027. Because the company is pre-revenue for its lead asset, its equity story centers on clinical data, regulatory milestones, and its ability to fund late-stage development.
Several verified events have shaped CRDF's price action over the past 30 days. On November 12, 2026, Cardiff reported third-quarter results: a GAAP net loss of $8.9 million, narrowed from $11.3 million a year earlier, and an EPS of -$0.12 that beat consensus expectations. Management indicated that cash, cash equivalents, and short-term investments of approximately $33.8 million are projected to fund operations into the third quarter of 2027, though additional capital will be needed to initiate the Phase 3 program.
On November 16, 2026, the company announced that the FDA granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab for adults with KRAS- or NRAS-mutated metastatic colorectal cancer, supported by data from CRDF-004. The news triggered a sharp rally on notably elevated volume. Earlier in the period, on October 22, shareholders approved an increase in authorized shares, expanding capital-raising flexibility but raising dilution concerns. On October 27, the company appointed Leila Alland, MD, as interim Chief Medical Officer. Separately, the ongoing dispute with Nerviano Medical Sciences over patent inventorship continues to weigh on sentiment, even as Cardiff maintains it has not breached its license agreement.
Looking ahead, investors are likely to focus on several catalysts and risks. The planned initiation of the CRDF-005 Phase 3 registrational trial, potentially in the first quarter of 2027, is the central event, along with the company's ability to secure the additional capital required to fund it. The December 2026 ASH presentation of CMML data could offer incremental validation of onvansertib beyond mCRC. The resolution of the Nerviano inventorship dispute remains a significant overhang, given its potential implications for the onvansertib license, which has a patent expiry in 2030 with a possible term extension to 2035. Continued cash-burn discipline, progress on companion-diagnostic regulatory activities, and EMA scientific advice on Phase 3 plans will also be closely watched. As with all clinical-stage biotechs, clinical, regulatory, and financing outcomes carry meaningful risk. From what I see, the upcoming data readouts will be particularly telling for the program's broader potential.
I’ve found Tickeron’s AI Trading Bots useful when evaluating volatile clinical-stage names like this one. The platform provides a range of automated strategies across different timeframes and risk profiles, which can help compare systematic approaches without relying on any single signal. It serves as a practical starting point for those interested in data-driven methods to manage exposure in the sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for CRDF entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 252 similar instances where the Aroon Indicator formed such a pattern. In 215 of the 252 cases the stock moved lower. This puts the odds of a downward move at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRDF's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 58 cases where CRDF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on CRDF as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CRDF just turned positive on November 16, 2026. Looking at past instances where CRDF's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (3.596). P/E Ratio (-1.326) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology